Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 27;16(19):3307.
doi: 10.3390/cancers16193307.

First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study

Massimo Martino  1   2 , Mercedes Gori  3 , Gaetana Porto  1   2 , Giorgia Policastro  1   2 , Martina Pitea  1   2 , Annalisa Sgarlata  1   2 , Ilaria Maria Delfino  1   2 , Francesca Cogliandro  1   2 , Anna Scopelliti  2 , Giovanna Utano  1   2 , Maria Pellicano  2 , Aurora Idato  1   2 , Iolanda Donatella Vincelli  1   2 , Violetta Marafioti  1   2 , Maria Caterina Micò  1   2 , Giuseppe Lazzaro  1   2 , Barbara Loteta  1   2 , Caterina Alati  1   2 , Giovanni Leanza  4 , Graziella D'Arrigo  5 , Giovanni Luigi Tripepi  5 , Annalisa Pitino  3
Affiliations

First-Line Use of Daratumumab in Patients with Multiple Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study

Massimo Martino et al. Cancers (Basel). .

Abstract

Background: This real-life study aimed to investigate the possible impact of D-VTd induction therapy on hematopoietic engraftment after autologous stem cell transplantation (auto-SCT).

Methods: Sixty consecutive NDMM patients received four cycles of induction therapy with D-VTd. The conditioning regimen consisted of melphalan 200 mg/m2. These patients were compared with a historical control group of 80 patients who received four cycles of VTd as induction therapy.

Results: The median days to reach neutrophil and platelet engraftment significantly differed between patients treated with D-VTd (11 and 13 days, respectively) and VTd (10 and 12 days). Univariate Cox analyses show that patients treated with D-VTd had a hazard ratio of neutrophil engraftment that was 42% significantly lower than those in the VTd arm (HR: 0.58, p = 0.002), and a multivariate model confirmed this result. Patients treated with D-VTd developed FN more frequently. Univariate and multivariate logistic regressions revealed an association between D-VTd and FN. Delayed engraftment did not correlate with more extended hospitalization. No patients died in the first six months after transplantation.

Conclusions: Our real-life study showed that a four-drug induction therapy containing DARA does not impact transplant safety outcomes.

Keywords: autologous stem cell transplantation; daratumumab; multiple myeloma; neutrophil and platelet engraftment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Absolute number of patients reaching neutrophil engraftment (absolute neutrophil count ≥0.5 × 109/L) by treatment group.
See this image and copyright information in PMC

References

    1. Ludwig H., Novis Durie S., Meckl A., Hinke A., Durie B. Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations between Health Access and Quality, Economic Resources, and Patient Empowerment. Oncologist. 2020;25:e1406–e1413. doi: 10.1634/theoncologist.2020-0141. - DOI - PMC - PubMed
    1. Gulla A., Anderson K.C. Multiple myeloma: The (r)evolution of current therapy and a glance into future. Haematologica. 2020;105:2358–2367. doi: 10.3324/haematol.2020.247015. - DOI - PMC - PubMed
    1. Kumar S.K., Callander N.S., Adekola K., Anderson L.D., Jr., Baljevic M., Baz R., Campagnaro E., Castillo J.J., Costello C., D’Angelo C., et al. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2023;21:1281–1301. doi: 10.6004/jnccn.2023.0061. - DOI - PubMed
    1. Wang P., Jin S.Y. Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma. World J. Clin. Cases. 2023;11:7091–7100. doi: 10.12998/wjcc.v11.i29.7091. - DOI - PMC - PubMed
    1. Voorhees P.M., Sborov D.W., Laubach J., Kaufman J.L., Reeves B., Rodriguez C., Chari A., Silbermann R., Costa L.J., Anderson L.D., et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10:e825–e837. doi: 10.1016/S2352-3026(23)00217-X. - DOI - PubMed

LinkOut - more resources